4.8 Review

Are patients with hepatocellular carcinoma and portal vein tumour thrombosis candidates for liver transplantation?

Journal

JOURNAL OF HEPATOLOGY
Volume 78, Issue 6, Pages 1124-1129

Publisher

ELSEVIER
DOI: 10.1016/j.jhep.2023.03.032

Keywords

Hepatocellular carcinoma; Liver transplantation; Portal vein tumour thrombosis; Transplant benefit; Segmental and lobar PVTT; Downstaging modalities

Ask authors/readers for more resources

In this debate, the authors discuss the suitability of liver transplantation for patients with hepatocellular carcinoma and portal vein tumor thrombosis. The argument for liver transplantation is based on the belief that it provides greater clinical benefits in terms of survival outcomes compared to palliative systemic therapy after successful downstaging treatment. The counterargument is that the evidence for liver transplantation in this setting is limited, and expected survival in these patients may still be lower than the accepted thresholds for liver transplantation.
In this debate, the authors consider whether patients with hepatocellular carcinoma (HCC) and portal vein tumour thrombosis are candidates for liver transplantation (LT). The argument for LT in this context is based on the premise that, following successful downstaging treatment, LT confers a much greater clinical benefit in terms of survival outcomes than the available alternative (palliative systemic therapy). A major argument against relates to limitations in the quality of evidence for LT in this setting - in relation to study design, as well as heterogeneity in patient characteristics and downstaging protocols. While acknowledging the superior outcomes offered by LT for patients with portal vein tumour thrombosis, the counterargument is that expected survival in such patients is still below accepted thresholds for LT and, indeed, the levels achieved for other patients who receive transplants beyond the Milan criteria. Based on the available evidence, it seems too early for consensus guidelines to recommend such an approach, however, it is hoped that with higher quality evidence and standardised downstaging protocols, LT may soon be more widely indicated, including for this population with high unmet clinical need. (c) 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available